Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?

NCT04510623 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.

NCT NCT04510623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04510623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?
Lead sponsor
University of British Columbia
Phase
Observational
Overall status
Unknown status
Start date
March 17, 2020
Completion date
June 30, 2022
Enrollment
500 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2